Form 8-K - Current report:
SEC Accession No. 0001193125-24-238425
Filing Date
2024-10-17
Accepted
2024-10-17 07:11:59
Documents
13
Period of Report
2024-10-14
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d891074d8k.htm   iXBRL 8-K 35474
  Complete submission text file 0001193125-24-238425.txt   157658

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sage-20241014.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20241014_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20241014_pre.xml EX-101.PRE 10811
16 EXTRACTED XBRL INSTANCE DOCUMENT d891074d8k_htm.xml XML 3555
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 241375923
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)